Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance.

ABSTRACT:

Background

Several vaccines with demonstrated efficacy for coronavirus disease 2019 (Covid-19) are available. The purpose of this study was to evaluate the COVID mRNA based and adenovector based vaccines' differential effectiveness during the time of circulation of the Delta variant and determine what impact this would have on population health and cost effectiveness.

Methods

We used de-identified claims in a research database that included vaccination status and Covid-positivity status. Individuals ≥18 years, fully vaccinated with Ad26.COV2·S/J&J/Janssen, mRNA-1273/Moderna, or BNT162b2/Pfizer-BioNTech by September 30, 2021, were included. Outcomes were SARS-CoV-2-infection, emergency department visits, outpatient visits, inpatient hospitalizations, intensive care unit (ICU)

SUBMITTER: Islam N 

PROVIDER: S-EPMC10156649 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature